GSK says asthma drug Breo shows superior results over standard care in major study
pharmafile | May 24, 2016 | News story | Research and Development, Sales and Marketing | COPD, GSK, asthma, breo, drug trial
UK drugmaker GlaxoSmithKline (LSE: GSK) on Tuesday said inhaled medicine Breo proved significantly better than standard care in a major study designed to test everyday use.
The study results reverse the setback in September last year after a big study for Breo found it failed to improve survival in people with COPD.
The study tested Breo in day-to-day practise across Salford and South Manchester and showed it was superior in reducing serious phases of breathing difficulties for patients with chronic obstructive pulmonary disease (COPD).
Eric Dube, SVP and Head, Global Respiratory Franchise, GSK, said: “The Salford Lung Study COPD results support the effectiveness of Relvar.”
There was a statistically significant reduction of 8.4 percent in the rate of moderate or severe exacerbations compared with those receiving usual care, the company said.
Lead investigator, Jørgen Vestbo, said: “The Salford Lung Study is a very important trial to help us understand more about the medicines we prescribe on a day-to-day basis. This is an important finding; what we are seeing today is the tip of the iceberg. Over the coming months we will understand more about the day-to-day effectiveness of FF/VI and how treatment choice, patient behaviour, co-morbidities and other factors combine to influence COPD outcomes.”
Chronic obstructive pulmonary disease (COPD) is a disease of the lungs that includes chronic bronchitis, emphysema or both. COPD is characterised by obstruction to airflow that interferes with normal breathing. Cigarette smoke, breathing in second-hand smoke, air pollution including biomass fuels, chemical fumes and dust from the environment or workplace can all contribute to COPD.
Anjali Shukla
Related Content
GSK’s Jemperli accepted for FDA review for endometrial cancer treatment
GSK has announced that the US Food and Drug Administration (FDA) has accepted its supplemental …
GSK shares results from phase 3 trial for gonorrhoea treatment
GSK has announced positive results from its phase 3 EAGLE-1 trial for gepotidacin, a potential …
GSK’s meningococcal vaccine candidate accepted for FDA review
GSK has announced that the US Food and Drug Administration (FDA) has accepted for review …
